Geovax Labs Inc (OTCMKTS:GOVX) – Analysts at Zacks Investment Research issued their Q2 2019 earnings per share estimates for Geovax Labs in a note issued to investors on Monday, June 10th. Zacks Investment Research analyst J. Vandermosten anticipates that the biotechnology company will post earnings of ($0.98) per share for the quarter. Zacks Investment Research also issued estimates for Geovax Labs’ Q3 2019 earnings at ($0.81) EPS, Q4 2019 earnings at ($0.52) EPS and FY2021 earnings at ($1.48) EPS.
GOVX stock opened at $0.87 on Wednesday. Geovax Labs has a fifty-two week low of $0.71 and a fifty-two week high of $25.00. The company has a market cap of $536,000.00, a P/E ratio of -0.09 and a beta of 0.78.
Geovax Labs (OTCMKTS:GOVX) last released its earnings results on Monday, May 13th. The biotechnology company reported ($1.43) earnings per share for the quarter. The company had revenue of $0.36 million for the quarter.
Geovax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers.
See Also: What is a capital gains distribution?
Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.